Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 20/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | HRH3 | Q9Y5N1 | 19/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodophenpropit SCHEMBL114508 | 1.00 | HRH4 (1.00) | HRH4TP53CYP1A2CYP3A4MEN1 | |
| Iodophenpropit SCHEMBL30632137 | 0.99 | HRH4 (1.00) | HRH4TP53CYP1A2CYP3A4MEN1 | |
| SCHEMBL26687384 | 0.81 | HRH4 (0.69) | HRH4TP53CYP1A2CYP3A4MEN1 | |
| Clobenpropit SCHEMBL49050 | 0.78 | HRH4 (1.00) | HRH4TP53CYP1A2CYP3A4MEN1 | |
| SCHEMBL9534159 | 0.78 | HRH4 (1.00) | HRH4TP53CYP1A2CYP3A4HRH3 | |
| SCHEMBL8805366 | 0.77 | HRH4 (0.63) | HRH4TP53CYP1A2CYP3A4MEN1 | |
| SCHEMBL9533886 | 0.71 | HRH4 (0.58) | HRH4TP53CYP1A2CYP3A4MEN1 | |
| SCHEMBL7859117 | 0.67 | HRH4 (1.00) | HRH4HRH3 | |
| SCHEMBL8621926 | 0.65 | HRH3 (0.60) | HRH4TP53CYP1A2CYP3A4MEN1 | |
| Clobenpropit SCHEMBL19733457 | 0.63 | HRH4 (0.65) | HRH4TP53CYP1A2CYP3A4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230346879-A1 | COMPOSITIONS AND METHODS FOR COMBINATORIAL DRUG DISCOVERY IN NANOLITER DROPLETS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2023-11-02 | — | — | US | claimed |
| US-11564970-B2 | Compositions and methods for combinatorial drug discovery in nanoliter droplets | THE BROAD INSTITUTE, INC. (US) | 2023-01-31 | — | — | US | claimed |
| US-20250367232-A1 | HALOGEN TREATMENT OF HEART ATTACK AND ISCHEMIC INJURY | HUTCHINSON FRED CANCER RES (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250078957-A1 | Unsupervised Machine Learning Methods | AMPEL BIOSOLUTIONS LLC (US) | 2025-03-06 | — | — | US | disclosed |
| US-20250022541-A1 | Unsupervised Machine Learning Methods | AMPEL BIOSOLUTIONS LLC (US) | 2025-01-16 | — | — | US | disclosed |
| US-20240428948-A1 | Unsupervised Machine Learning Methods | AMPEL BIOSOLUTIONS LLC (US) | 2024-12-26 | — | — | US | disclosed |
| EP-4479973-A1 | UNSUPERVISED MACHINE LEARNING METHODS | Ampel Biosolutions, LLC (US) | 2024-12-25 | — | — | EP | disclosed |
| US-12016880-B2 | Halogen treatment of heart attack and ischemic injury | FRED HUTCHINSON CANCER CENTER (US) | 2024-06-25 | — | — | US | disclosed |
| EP-3104939-B1 | TREATMENT OF HEART ATTACK AND ISCHEMIC INJURY WITH SODIUM IODIDE | FRED HUTCHINSON CANCER CENTER (US) | 2024-05-01 | — | — | EP | disclosed |
| US-20240100018-A1 | COMPOUNDS FOR THE TREATMENT OF A DISEASE OR DISORDER, METHODS FOR IDENTIFYING SAID COMPOUNDS | CEDARS-SINAI MEDICAL CENTER | 2024-03-28 | — | — | US | disclosed |
| US-20230346879-A1 | COMPOSITIONS AND METHODS FOR COMBINATORIAL DRUG DISCOVERY IN NANOLITER DROPLETS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2023-11-02 | — | — | US | disclosed |
| WO-2023158713-A1 | UNSUPERVISED MACHINE LEARNING METHODS | AMPEL BIOSOLUTIONS, LLC (US) | 2023-08-24 | — | — | WO | disclosed |
| US-11564970-B2 | Compositions and methods for combinatorial drug discovery in nanoliter droplets | THE BROAD INSTITUTE, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| US-11564970-B2 | Compositions and methods for combinatorial drug discovery in nanoliter droplets | THE BROAD INSTITUTE, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| US-20220387483-A1 | USE OF IODIDE COMPOUNDS FOR THE TREATMENT AND PREVENTION OF CHEMOTHERAPY-ASSOCIATED CACHEXIA AND CARDIOTOXICITY | FARADAY PHARMACEUTICALS INC (US) | 2022-12-08 | — | — | US | disclosed |
| US-20220313730-A1 | HALOGEN TREATMENT OF HEART ATTACK AND ISCHEMIC INJURY | FRED HUTCHINSON CANCER CENTER | 2022-10-06 | — | — | US | disclosed |
| EP-4054593-A1 | USE OF IODIDE COMPOUNDS FOR THE TREATMENT AND PREVENTION OF CHEMOTHERAPY-ASSOCIATED CACHEXIA AND CARDIOTOXICITY | Faraday Pharmaceuticals, Inc. (US) | 2022-09-14 | — | — | EP | disclosed |
| US-20200353033-A1 | COMPOSITIONS AND METHODS FOR COMBINATORIAL DRUG DISCOVERY IN NANOLITER DROPLETS | THE BROAD INSTITUTE, INC. (US) | 2020-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230346879-A1 | COMPOSITIONS AND METHODS FOR COMBINATORIAL DRUG DISCOVERY IN NANOLITER DROPLETS | RAB5IF, CLTB, TBK1 | HRH4 4196/4885TP53 2153/4885CYP1A2 4441/4885 |
| US-20200353033-A1 | COMPOSITIONS AND METHODS FOR COMBINATORIAL DRUG DISCOVERY IN NANOLITER DROPLETS | RAB5IF, CLTB, TBK1 | HRH4 4196/4885TP53 2153/4885CYP1A2 4441/4885 |
| US-11564970-B2 | Compositions and methods for combinatorial drug discovery in nanoliter droplets | RAB5IF, LIPA, CLTB | HRH4 3614/4885TP53 3037/4885CYP1A2 4134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.